title: Intraovarian transplantation of primordial follicles fails to rescue chemotherapy injured ovaries.
abstract: Busulfan and cyclophosphamide (B/C)-treated mice exhibited a marked increase in apoptosis and a concomitant decrease in the ovarian weight. Histological and RT-PCR analysis indicate that the period of germ cell depletion in the B/C-treated ovaries coincides with decreased expression of genes Figla, Lhx8, Nobox, c-kit, and Sox3. However, depletion of the ovarian germ cells is mediated by autophagy-independent pathways that involve Fas/FasL-, TNF-, and/or p53-signalings. Treatment with B/C resulted in the cease of the reproductive function to produce their offspring during the 15(th) week post-treatment period in female mice. Furthermore, injection of the 3 × 10(6) GFP positive primordial follicles into the ovaries of the B/C treated mouse did not show apparent colonization of the transplanted follicles within the recipient ovaries. The present results suggest that B/C treatment is closely associated with an increased risk of premature ovarian failure.
authors: Department of Animal Biotechnology, College of Animal Bioscience & Technology, KonKuk University, Seoul 143-701, Republic of Korea.
authors: Mi-Ryung
authors: MR
authors: Park
authors: Yun-Jung
authors: YJ
authors: Choi
authors: Deug-Nam
authors: DN
authors: Kwon
authors: Chankyu
authors: C
authors: Park
authors: Hong-Thuy
authors: HT
authors: Bui
authors: Sangiliyandi
authors: S
authors: Gurunathan
authors: Ssang-Goo
authors: SG
authors: Cho
authors: Hyuk
authors: H
authors: Song
authors: Han Geuk
authors: HG
authors: Seo
authors: Gyesik
authors: G
authors: Min
authors: Jin-Hoi
authors: JH
authors: Kim
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D015415:Biomarkers; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D053222:Fas Ligand Protein / Q000235:genetics / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D008297:Male; D051379:Mice; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D006080:Ovarian Follicle / Q000378:metabolism / Q000637:transplantation*; D010053:Ovary / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*; D010063:Ovum / Q000187:drug effects; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D012098:Reproduction / Q000187:drug effects; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D019014:fas Receptor / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D053222:Fas Ligand Protein; D014409:Tumor Necrosis Factor-alpha; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor; D003520:Cyclophosphamide; D019009:Proto-Oncogene Proteins c-kit; D002066:Busulfan